Literature DB >> 7633017

Multiorgan failure associated with lomustine overdose.

K C Trent1, L Myers, J Moreb.   

Abstract

OBJECTIVE: To report a lomustine overdose in a patient with anaplastic astrocytoma. CASE
SUMMARY: A 28-year-old woman with anaplastic astrocytoma was treated with partial resection and radiation therapy followed by a lomustine-containing regimen. The patient took lomustine 1400 mg po over a week, her regular dose being 200 mg on day 1 of the regimen. Pancytopenia developed within a week after the last dose of lomustine and the patient was admitted to the bone marrow transplant unit for supportive care. About 3 weeks later, the patient gradually developed a multiorgan dysfunction, including liver, brain, and lungs without evidence of infection or tumor progression, and died on day 45 of hospitalization. DISCUSSION: This is the third reported case of lomustine overdose that resulted from supplying the patient with more tablets than needed for 1 dose. Although late hematopoietic recovery may be possible after such a high dose of lomustine, other organ toxicities might be detrimental.
CONCLUSIONS: Physicians and pharmacists should avoid supplying more tablets than needed for 1 lomustine dose. High doses of lomustine may cause irreversible multiorgan toxicities.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7633017     DOI: 10.1177/106002809502900409

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  2 in total

1.  Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.

Authors:  Kader Yagiz; Tiffany T Huang; Fernando Lopez Espinoza; Daniel Mendoza; Carlos E Ibañez; Harry E Gruber; Douglas J Jolly; Joan M Robbins
Journal:  Neuro Oncol       Date:  2016-05-10       Impact factor: 12.300

2.  The management of lomustine overdose in malignant glioma patients.

Authors:  Hans-Georg Wirsching; Isabel Tritschler; Antonella Palla; Christoph Renner; Michael Weller; Ghazaleh Tabatabai
Journal:  Neurooncol Pract       Date:  2014-09-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.